Navigation Links
NewCardio Announces Financial Results for Its 2010 Third Quarter
Date:11/15/2010

eaders and regulators, with management presenting data, speaking at or chairing events at a variety of conferences, including the Cambridge Healthtech Institute (CHI) inaugural conference entitled "Mitigating Safety Risks in Early Clinical Development," and the Diabetic Drug Safety Conference meeting entitled "Development of Type 2 Diabetes Mellitus Drugs: State-of-the-Art Cardiovascular Safety Assessments." In addition, a clinical study of the my3KG titled "Vectorcardiographic and Electrocardiographic Criteria to Distinguish New and Old Left Bundle Branch Block," has been published in the August 2010 issue of the peer-reviewed journal, Heart Rhythm, the official journal of the Heart Rhythm Society.

Financial ResultsNewCardio generated revenue, derived from professional services associated with the deployment of QTinno for use in the cardiac safety component of a drug development study, as well as initial per ECG revenues from the first two studies, totaling $99,210 with no corresponding revenue in the prior year quarter. Net cash used in operating activities was $852,000 in the current quarter, which is a decrease of 43% compared to $1.5 million in both the third quarter last year and the immediately prior quarter of this year, as the Company implemented an initiative to reduce its cash usage by 30-35%. For the quarter, the Company reported a net loss attributable to common shareholders of $2.5 million, or $(0.08) per fully diluted share, compared to a net loss attributable to common shareholders of $3.4 million, or $(0.14) per fully diluted share, in the third quarter last year. The net loss per share was based on 29.5 million and 23.9 million weighted average shares outstanding, respectively.

For the nine months ending September 30, 2010, the Company reported revenue of $169,328, compared to no revenue in the prior year. For the nine months ending September 30, 2010, the Company's net loss attributable to common shareholders was $8.3 millio
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NewCardio Announces Positive Results From Third Clinical Validation Study
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Leadership to Present Two Abstracts at ISCE Conference
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio CEO Increases Equity Position
8. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Dallas, TX (PRWEB) , ... August 28, 2015 , ... ... Surgical Center is taking part with their subsidiary USPI Tenet Health. , The American ... to fight heart disease and stroke. They believe that together, a difference can be ...
(Date:8/28/2015)... ... , ... The 6th Annual Survivor in the City, Chicago silent auction ... accolade to its cadre of widespread support—an official letter of support and gratitude from ... medical community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... centers did as well, 266,604 fewer patients would die ... -- Patients in the top-ranked hospitals in the United ... those in the lowest-rated hospitals, according to a new ... 10th annual HealthGrades Hospital Quality in America Study looked ...
... mechanisms involved in resistance to treatment of breast cancer ... Press in the October issue of the journal ... identify patients who are unlikely to respond to trastuzumab ... patients. , Trastuzumab is an antibody used as a ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
... Nine of Texas, 181,legislators are being honored ... of their accomplishments on behalf of health care,during ... Texas Hospital,Association created the award in 1997 to ... outstanding leadership on issues important,to hospitals and health ...
... NEW YORK, Oct. 15 L,Oreal Paris, the worldwide ... Mexoryl SX (ecamsule), a new daily moisturizer with advanced ... rays -- the number,one cause of skin aging. After ... exclusive to L,Oreal, has been,approved in a formula by ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Genetic approach provides new insight into trastuzumab resistance in breast cancer 2Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Video: New FDA-Approved Sun Protectant Saves Skin All Year Round 2
Angled, cannula with 32 gauge tip, 4 mm long, angled 65 degrees 1 mm from tip. 10 per box....
Comfortable 3M hypoallergenic medical foam adhesive. Extra adhesive bandages for eye shield sets. 25 packages of 4 each....
Includes one aluminum Fox eye shield and one eye Garter shield cover. Packaged 50 per box. White only....
Includes one aluminum pediatric eye shield and one eye garter shield cover. Packaged 50 per box. White only....
Medicine Products: